$ATEX

Anterix (NASDAQ: ATEX) chair sells 10K shares near $91

Anterix (ATEX) Executive Chairman Thomas R. Kuhn exercised 10,000 stock options at $33.62 per share and sold 10,000 shares at an average price of $89, plus 1,654 shares at $79.52 to cover taxes. He also received a grant of 2,791 restricted stock units.

Original reporting
Published Aug 26, 2026, 8:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ATEX
Bearish
medium confidence
Mentioned
$ATEX
Relevance
5/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ATEXBearishLow
01

Why it matters

The disclosed insider transaction provides fresh data for short‑term traders; the modest size suggests limited market impact.

02

Market read

New insider transaction adds to ATEX's trading narrative; may influence short‑term sentiment.

03

What to watch

Potential upcoming contract announcements or earnings could offset the negative signal from the insider sale.

Relevance 5/10Novelty 6/10Timing: post‑sale on Aug 24 2026

Background

Form 4 filing by Anterix Inc. (NASDAQ: ATEX) reporting option exercise and share sales by its Executive Chairman.

Company-level read

Ticker impact

$ATEXBearishMedium confidence
Context

Executive Chairman Thomas R. Kuhn exercised 10,000 options and sold the shares at $88‑$91 on Aug 24, 2026, a new Form 4 filing.

Expected impact

Potential short‑term pressure on ATEX price; limited upside unless other catalysts emerge.

Evidence & confidence

The sale is a primary disclosure; however, the amount is relatively small and typical for tax withholding, limiting material impact.

Market effects

Minimal impact on the satellite communications sector; insider activity is company‑specific.

No broader regional effect.

Limited to investors tracking micro‑cap insider activity.

Counterpoint

The sale could be routine tax withholding rather than a lack of confidence, so price may remain stable.

Key entities

  • Thomas R. Kuhn

    Director and Executive Chairman of Anterix who exercised options and sold shares.

  • Anterix Inc.

    NASDAQ‑listed provider of satellite communications infrastructure.

Related articles

$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi